{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:35:54Z","timestamp":1793684154960,"version":"4.5.1"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"HHS | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"crossref","award":["P30-ES013508"],"award-info":[{"award-number":["P30-ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32-GM133398"],"award-info":[{"award-number":["T32-GM133398"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,19]]},"abstract":"<jats:p>Androgen receptor signaling inhibitors (ARSI) are used to treat castration-resistant prostate cancer (CRPC) to stop a resurgence of androgen receptor (AR) signaling. Despite early success, patients on ARSIs eventually relapse, develop drug resistance, and succumb to the disease. Resistance may occur through intratumoral steroidogenesis mediated by upregulation of aldo-keto reductase family 1C member 3 (AKR1C3). Patients treated with leuprolide (castrate) and those treated with leuprolide plus abiraterone (post-Abi) harbor a reservoir of DHEA-S which could fuel testosterone (T) biosynthesis via AKR1C3 to cause a resurgence of prostate cancer cell growth. We demonstrate that concentrations of DHEA-S found in castrate and post-Abi patients are (i) converted to T in an AKR1C3-dependent manner in prostate cancer cells, and (ii) in amounts sufficient to stimulate AKR1C3-dependent cell growth. We observed this in primary and metastatic prostate cancer cell lines, CWR22PC and DuCaP, respectively. Androgen measurements were made by stable isotope dilution LC-MS\/MS. We demonstrate AKR1C3 dependence using stable short hairpin RNA knockdown and pharmacologic inhibitors. We also demonstrate that free DHEA is reduced to 5-androstene-3\u03b2,17\u03b2-diol (5-Adiol) by AKR1C3 and that this is a major metabolite, suggesting that in our cell lines 5-Adiol is a predominant precursor of T. We have identified a mechanism of ARSI resistance common to both primary and metastatic cell lines that is dependent on the conversion of DHEA to 5-Adiol on route to T catalyzed by AKR1C3.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We show that reservoirs of DHEA-S that remain after ARSI treatment are converted into T in primary and metastatic prostate cancer cells in amounts sufficient to stimulate cell growth. Pharmacologic and genetic approaches demonstrate that AKR1C3 is required for these effects. Furthermore, the route to T proceeds through 5-Adiol. We propose that this is a mechanism of ARSI drug resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0235","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:27:15Z","timestamp":1693214835000},"page":"1888-1898","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3\u03b2,17\u03b2-Diol"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-2245","authenticated-orcid":true,"given":"Andrea J.","family":"Detlefsen","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-2038","authenticated-orcid":true,"given":"Clementina A.","family":"Mesaros","sequence":"additional","affiliation":[{"name":"2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"3Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3884-0808","authenticated-orcid":true,"given":"Ling","family":"Duan","sequence":"additional","affiliation":[{"name":"2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-1066","authenticated-orcid":true,"given":"Trevor M.","family":"Penning","sequence":"additional","affiliation":[{"name":"2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"3Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"2023091914062318800_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023091914062318800_bib2","first-page":"293","article-title":"Studies","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"2023091914062318800_bib3","first-page":"52","article-title":"Effective testosterone suppression for prostate cancer: is there a best castration therapy?","volume":"11","author":"Gomella","year":"2009","journal-title":"Rev Urol"},{"key":"2023091914062318800_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0149-2918(96)80215-3","article-title":"Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer","volume":"18","author":"Sharifi","year":"1996","journal-title":"Clin Ther"},{"key":"2023091914062318800_bib5","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-08-2660","article-title":"Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer","volume":"15","author":"Knudsen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023091914062318800_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tem.2010.01.002","article-title":"Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer","volume":"21","author":"Knudsen","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"2023091914062318800_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2023091914062318800_bib8","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023091914062318800_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"2023091914062318800_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"2023091914062318800_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2023091914062318800_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2023091914062318800_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"key":"2023091914062318800_bib14","first-page":"1273","article-title":"Colocalization of androgen receptor gene mutations in prostate cancer","volume":"7","author":"Buchanan","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2023091914062318800_bib15","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"J Clin Invest"},{"key":"2023091914062318800_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"2023091914062318800_bib17","first-page":"2511","article-title":"Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist","volume":"59","author":"Taplin","year":"1999","journal-title":"Cancer Res"},{"key":"2023091914062318800_bib18","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-12-1335","article-title":"Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors","volume":"72","author":"Mitsiades","year":"2012","journal-title":"Cancer Res"},{"key":"2023091914062318800_bib19","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"2023091914062318800_bib20","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1158\/1078-0432.CCR-13-3483","article-title":"Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer","volume":"20","author":"Fankhauser","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2023091914062318800_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsbmb.2011.12.012","article-title":"Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride","volume":"130","author":"Byrns","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023091914062318800_bib22","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1073\/pnas.1107898108","article-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","volume":"108","author":"Chang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023091914062318800_bib23","first-page":"1971","article-title":"Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha\/17 beta-HSD activity and cellular distribution","volume":"11","author":"Lin","year":"1997","journal-title":"Mol Endocrinol"},{"key":"2023091914062318800_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tem.2004.09.004","article-title":"The backdoor pathway to dihydrotestosterone","volume":"15","author":"Auchus","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"2023091914062318800_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem J"},{"key":"2023091914062318800_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/ijms22020487","article-title":"Steroidogenesis in peripheral and transition zones of human prostate cancer tissue","volume":"22","author":"Deb","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023091914062318800_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"2023091914062318800_bib28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine Androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"2023091914062318800_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2023091914062318800_bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jcp.2007.050906","article-title":"Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer","volume":"61","author":"Wako","year":"2008","journal-title":"J Clin Pathol"},{"key":"2023091914062318800_bib31","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1111\/jcmm.15831","article-title":"The AKR1C3\/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression","volume":"24","author":"Wang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2023091914062318800_bib32","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1158\/1078-0432.CCR-13-1151","article-title":"Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth","volume":"19","author":"Yepuru","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023091914062318800_bib33","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023091914062318800_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cbi.2014.12.012","article-title":"The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer","volume":"234","author":"Tamae","year":"2015","journal-title":"Chem Biol Interact"},{"key":"2023091914062318800_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","article-title":"Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT)","volume":"171","author":"Ternov","year":"2022","journal-title":"Eur J Cancer"},{"key":"2023091914062318800_bib36","doi-asserted-by":"crossref","first-page":"e030218","DOI":"10.1136\/bmjopen-2019-030218","article-title":"Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol","volume":"9","author":"Kvorning Ternov","year":"2019","journal-title":"BMJ Open"},{"key":"2023091914062318800_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2021.05.003","article-title":"A prospective study of the relationship between clinical outcomes after enzalutamide and serum androgen levels measured via liquid chromatography-tandem mass spectrometry in patients with castration-resistant prostate cancer","volume":"29","author":"Miyazawa","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"2023091914062318800_bib38","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1210\/en.2006-0627","article-title":"Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer","volume":"147","author":"Bauman","year":"2006","journal-title":"Endocrinology"},{"key":"2023091914062318800_bib39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.steroids.2004.09.014","article-title":"Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase\/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate","volume":"69","author":"Lin","year":"2004","journal-title":"Steroids"},{"key":"2023091914062318800_bib40","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J Med Chem"},{"key":"2023091914062318800_bib41","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/me.2002-0436","article-title":"Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis","volume":"17","author":"Marijanovic","year":"2003","journal-title":"Mol Endocrinol"},{"key":"2023091914062318800_bib42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1210\/me.2005-0287","article-title":"Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease","volume":"20","author":"Bauman","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2023091914062318800_bib43","doi-asserted-by":"crossref","first-page":"bqac068","DOI":"10.1210\/endocr\/bqac068","article-title":"Conversion of classical and 11-oxygenated androgens by insulin-induced AKR1C3 in a model of human PCOS adipocytes","volume":"163","author":"Paulukinas","year":"2022","journal-title":"Endocrinology"},{"key":"2023091914062318800_bib44","doi-asserted-by":"crossref","first-page":"106121","DOI":"10.1016\/j.jsbmb.2022.106121","article-title":"Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase)","volume":"221","author":"Detlefsen","year":"2022","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023091914062318800_bib45","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem Rev"},{"key":"2023091914062318800_bib46","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/jm00170a008","article-title":"Antiandrogenic steroidal sulfonylpyrazoles","volume":"33","author":"Christiansen","year":"1990","journal-title":"J Med Chem"},{"key":"2023091914062318800_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10637-014-0101-x","article-title":"Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I\/II study","volume":"32","author":"Loriot","year":"2014","journal-title":"Invest New Drugs"},{"key":"2023091914062318800_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.192","article-title":"A phase Ib\/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC)","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023091914062318800_bib49","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/pros.24587","article-title":"3\u03b2HSD activity saturates at physiological substrate concentrations in intact cells","volume":"83","author":"McManus","year":"2023","journal-title":"Prostate"},{"key":"2023091914062318800_bib50","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","article-title":"HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study","volume":"17","author":"Hearn","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023091914062318800_bib51","doi-asserted-by":"crossref","first-page":"E3816","DOI":"10.1073\/pnas.1702211114","article-title":"Estrogen receptor beta, a regulator of androgen receptor signaling in the mouse ventral prostate","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023091914062318800_bib52","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/0008-5472.CAN-04-1941","article-title":"The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype","volume":"65","author":"Guerini","year":"2005","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0235\/3360812\/crc-23-0235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1888\/3364951\/crc-23-0235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1888\/3364951\/crc-23-0235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T10:07:32Z","timestamp":1695118052000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/9\/1888\/729109\/AKR1C3-Converts-Castrate-and-Post-Abiraterone-DHEA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0235","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24162497.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162494.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162494","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162488.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162491","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162485.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162512","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162503.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162497","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162491.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162488","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162512.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162509","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162500.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162506.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162509.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24162506","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6842009.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6842009","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]}}}